PET/CT

What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence

by

For the majority of patients at high-risk for biochemical recurrence of prostate cancer (PCa), new prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) research reaffirms a lack of sustained efficacy for monotherapy treatment with local radiation therapy or radical prostatectomy. For the retrospective study, recently published in BJUI Compass, researchers reviewed PSMA PET/CT data … Read more

Diagnostic Imaging's Weekly Scan: May 4 — May 10 – diagnosticimaging.com

by

Diagnostic Imaging’s Weekly Scan: May 4 — May 10  diagnosticimaging.com Source link

Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging

by

Emerging research suggests that hormone therapy has no significant impact upon the diagnostic efficacy of 18F-piflufolastat PET/CT for detecting recurrent or metastatic prostate cancer. For the retrospective study, recently published in The Prostate, researchers evaluated the use of 18F-piflufolastat PET/CT (Pylarify, Lantheus) in 93 patients with elevated prostate-specific antigen (PSA) levels and suspected local recurrence … Read more